Effect of sequential applications of topical tacrolimus and topical corticosteroids in the treatment of pediatric atopic dermatitis: An open-label pilot.

Slides:

Advertisements

Similar presentations

Serum vitamin D status in adult patients with atopic dermatitis: Recommendations for daily practice Jorien van der Schaft, MD, PhD, Lieneke F.M. Ariens,

Advertisements

Molluscum contagiosum infection during the treatment of vitiligo with tacrolimus ointment Bong Kyun Ahn, MD, Byoung-Dae Kim, MD, Sang Ju Lee, MD, Seung.

Optimal time to provide skin cancer and photoprotection education to pediatric solid organ transplant recipients Lily Chen, BA, Feng Gao, MD, PhD, MPH,

Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH

Yul W. Yang, MD, PhD, David J. DiCaudo, MD

Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients Lucy Y. Liu, BA, Brittany.

Use of Eczema Action Plans (EAPs) to improve parental understanding of treatment regimens in pediatric atopic dermatitis (AD): A randomized controlled.

A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children Mark Boguniewicz, MDa, Virginia C. Fiedler,

Baldness reversed by chemotherapy

Megan Wood, MD, Tom Raisanen, MD, Ingrid Polcari, MD

Ahmad Al Aboud, MD, Melissa Abrams, MD, Anthony J. Mancini, MD

Efficacy of simvastatin in plaque psoriasis: A pilot study

Hypertrichosis around a leg ulcer being treated with prostaglandin E1 ointment Tetsuya Honda, MD, PhD, Satoshi Koreeda, MD, PhD, Yoshiki Miyachi, MD,

Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD

Shawn G. Kwatra, BS, Hong Liang Tey, MRCP (UK), Saba M

Serum vitamin D status in adult patients with atopic dermatitis: Recommendations for daily practice Jorien van der Schaft, MD, PhD, Lieneke F.M. Ariens,

María Jesús Suárez Valladares, MD, Manuel Ángel Rodríguez Prieto, MD

Surveillance and assessment of occupational dermatitis using Rhode Island workers' compensation data 1998 to 2002 Irwin B. Horwitz, PhD, Brian P. McCall,

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild.

Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study Hsien-Yi Chiu, MD, Tsen-Fang.

Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial Catherine Maari, MD, FRCPC, Philippe Marchessault,

Ana Corcimaru, BS, Dean S. Morrell, MD, Craig N. Burkhart, MD

Sara A. Farber, BA, Sara Samimi, MD, Misha Rosenbach, MD

Pharmacy costs of specialty medications for plaque psoriasis in the United States Eric J. Yang, BS, Kristen M. Beck, MD, Sahil Sekhon, MD, Tina Bhutani,

A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis Lorinda Chung, MD, David Fiorentino,

Pilot study of a skin cancer education curriculum for medical students

Applying for dermatology residency is difficult and expensive

Reply to: “A note on normality”

Clinical and photographic assessment of lichen planopilaris treatment efficacy Aline Donati, MD, Philipe Assouly, MD, Bruno Matard, MD, Corinne Jouanique,

Google search trends for tanning salons: Temporal patterns indicate peak interest in mid spring Derek D. Reed, PhD, BCBA-D Journal of the American Academy.

Successful use of a modified Goeckerman regimen in the treatment of generalized prurigo nodularis Eric Sorenson, AB, Ethan Levin, MD, John Koo, MD, Timothy.

A survey-based study on nail examinations at an American Academy of Dermatology free skin cancer screening Dayoung Ko, BS, Shari R. Lipner, MD, PhD

Increased serum levels of interleukin 33 in patients with atopic dermatitis Risa Tamagawa-Mineoka, MD, PhD, Yasutaro Okuzawa, MD, Koji Masuda, MD, PhD,

Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks

Molluscum contagiosum infection during the treatment of vitiligo with tacrolimus ointment Bong Kyun Ahn, MD, Byoung-Dae Kim, MD, Sang Ju Lee, MD, Seung.

Lip edema Journal of the American Academy of Dermatology

Topical tacrolimus for chronic actinic dermatitis

Stephanie D. Gan, MD, Sarah H

Eva Wang, BS, John Koo, MD, Elie Levy, MD

Tacrolimus ointment in the treatment of dirty neck lesions in atopic dermatitis Kayako Hira, MD, Yasushi Suga, MD, PhD, Tomoyuki Monma, Kouichi Mitsuishi,

Lawrence F. Eichenfield, MD, Lisa Beck, MD

Dema T. Alniemi, MD, Laura McGevna, MD JAAD Case Reports

Anjali Shroff, MD, Emma Guttman-Yassky, MD, PhD JAAD Case Reports

Stefan Tukaj, PhD, Detlef Zillikens, MD, Michael Kasperkiewicz, MD

Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants Roland Kaufmann, MD, Regina Fölster-Holst, MD, Peter Höger, MD,

Hugh Gloster, MD, Chesahna Kindred, MBA

Medicaid acceptance among pediatric dermatologists

Linear morphea: Clinical characteristics, disease course, and treatment of the Morphea in Adults and Children cohort Elaine Kunzler, MD, Stephanie Florez-Pollack,

Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by.

Pruritus severity in patients with psoriasis is not correlated with psoriasis disease severity David Roblin, MD, FRCP, Ro Wickramasinghe, PhD, MBA, Gil.

Alopecia areata is associated with impaired health-related quality of life: A survey of affected adults and children and their families Lucy Y. Liu,

Jennifer L. Hundley, MD, Christie L

Christopher T. Cassetty, MD, Andrew F. Alexis, MD, MPH, Jerome L

Yu-Chen Huang, MD, Ying-Chih Cheng, MD

Modification of the nail psoriasis severity index

Tofacitinib therapy for children with severe alopecia areata

Tezepelumab, an anti–thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a.

A simple algorithm for evaluating dermatologic disease in critically ill patients: A study based on retrospective review of medical intensive care unit.

An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis James Krell, MD, FAAD, Candi Nelson, BS,

Gaps in pain management in dermatology: A needs assessment from Canada

Sirolimus for treatment of verrucous venous malformation: A retrospective cohort study Gaolei Zhang, MD, PhD, Hongguang Chen, MD, PhD, Zhen Zhen, MD,

Brittany G. Craiglow, MD, Brett A. King, MD, PhD

Lisa A. Beck, MD, Sarbjit Saini, MD

Brian B. Johnson, MD, Lisa A. Beck, MD, S. Shahzad Mustafa, MD

Randomized study of topical tacrolimus ointment as possible treatment for resistant idiopathic pruritus ani Erwin Suys, MD Journal of the American Academy.

Chieko Sadahira, MD, Kozo Yoneda, MD, PhD, Yasuo Kubota, MD, PhD

Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults Eric L. Simpson, MD, MCR,

Volume 5, Issue 7, Pages (July 2019)

Presentation transcript:

Effect of sequential applications of topical tacrolimus and topical corticosteroids in the treatment of pediatric atopic dermatitis: An open-label pilot study Yasuo Kubota, MD, Kozo Yoneda, MD, Kozo Nakai, MD, Junko Katsuura, MD, Tetsuya Moriue, MD, Yoshie Matsuoka, MD, Izumi Miyamoto, MD, Yukihiro Ohya, MD Journal of the American Academy of Dermatology Volume 60, Issue 2, Pages 212-217 (February 2009) DOI: 10.1016/j.jaad.2008.09.034 Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions

Fig 1 Schematic presentation of topical sequential therapy and data-sampling periods using Eczema Area and Severity Index, pruritus and sleep disturbance scores, and quality-of-life (QOL) survey. Journal of the American Academy of Dermatology 2009 60, 212-217DOI: (10.1016/j.jaad.2008.09.034) Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions

Fig 2 Change from baseline to end of treatment (for up to 12 weeks) in Eczema Area and Severity Index (EASI) scores in pediatric patients with atopic dermatitis. Significant improvement was observed throughout the course of sequential therapy (P < .001). Journal of the American Academy of Dermatology 2009 60, 212-217DOI: (10.1016/j.jaad.2008.09.034) Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions

Fig 3 Change from baseline to end of treatment (12 weeks) in patients' assessment of pruritus (A) and sleep disturbance (B) in pediatric patients with atopic dermatitis. Significant improvement was observed throughout the course of sequential therapy (P < .001). Journal of the American Academy of Dermatology 2009 60, 212-217DOI: (10.1016/j.jaad.2008.09.034) Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions

Fig 4 Clinical improvement of patient before (A) and after (B) 10 weeks of sequential therapy with tacrolimus ointment 0.03% and corticosteroid ointment (betamethasone valerate 0.12%). Journal of the American Academy of Dermatology 2009 60, 212-217DOI: (10.1016/j.jaad.2008.09.034) Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions

Fig 5 A, Children's Dermatology Life Quality Index (CDLQI). B, Infant's Dermatology Quality of Life (QOL) Index (IDQOL). QOL change scores from baseline to end of treatment (at maintenance phase). Significant improvement of QOL was observed throughout the course of sequential therapy (P < .05). Journal of the American Academy of Dermatology 2009 60, 212-217DOI: (10.1016/j.jaad.2008.09.034) Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions

Fig 6 A, Children's Dermatology Life Quality Index (CDLQI). B, Infant's Dermatology Quality of Life Index (IDQOL). Topical sequential therapy significantly improved areas in which atopic dermatitis has greatest impact, including symptoms/feelings (CDLQI, IDQOL) and sleep disturbance (CDLQI). Journal of the American Academy of Dermatology 2009 60, 212-217DOI: (10.1016/j.jaad.2008.09.034) Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions

Fig 7 Median difference between pretest (quality-of-life score before study) and retrospective pretest scores was significant at group level (P < .05), indicating that response shift bias was present. CDLQI, Children's Dermatology Life Quality Index. Journal of the American Academy of Dermatology 2009 60, 212-217DOI: (10.1016/j.jaad.2008.09.034) Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions